Managing Adverse Events in Novel Friedreich’s Ataxia Therapy

A key opinion leader outlines common adverse events associated with omaveloxolone treatment in Friedreich's ataxia patients and describes strategies used to manage or minimize these adverse effects.

EP: 1.Friedreich Ataxia: Addressing Treatment Objectives and Comorbidities

EP: 2.Guidelines & FDA Approval of Novel Friedreich Ataxia Therapy

EP: 3.Engaging mFARS Scale to Monitor Friedreich Ataxia Progression

Now Viewing

EP: 4.Managing Adverse Events in Novel Friedreich’s Ataxia Therapy

EP: 5.Examining Trial Data on Omaveloxolone Efficacy

EP: 6.Promising Therapy Approaches for Advanced Friedreich Ataxia

EP: 7.Friedreich Ataxia: Looking Forward at the Treatment Landscape

EP: 8.Epidemiology, Pathophysiology, and Symptomatology of Friedreich Ataxia

EP: 9.Diagnosis of Friedreich Ataxia

EP: 10.Impact of Friedreich Ataxia on Quality of Life

EP: 11.Clinical Utility of the Modified Friedreich Ataxia Rating Scale

EP: 12.Comorbidities and Complications Associated With Friedreich Ataxia

EP: 13.Challenges Associated With Friedreich Ataxia

EP: 14.Future Considerations for Friedreich Ataxia

What adverse events are typically encountered with omaveloxolone, what strategies do you employ to mitigate or address them effectively and under what circumstances should omaveloxolone be discontinued, if at all?

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Subscribe Now!